STRIFON FORTE DSC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for STRIFON FORTE DSC (STRIFON FORTE DSC).
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
| Metabolism | Caffeine is primarily metabolized by CYP1A2. Dihydroergotamine is metabolized by CYP3A4. Thioridazine is metabolized by CYP2D6. |
| Excretion | Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10% |
| Half-life | 10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly |
| Protein binding | 20-40% bound to serum albumin |
| Volume of Distribution | 0.8-1.0 L/kg, indicating distribution into total body water |
| Bioavailability | Oral: 100% (first-pass metabolism negligible) |
| Onset of Action | Oral: 30-60 minutes |
| Duration of Action | 4-8 hours for analgesia; 12-24 hours for antipyresis |
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; use with caution in severe renal impairment due to lack of data. |
| Liver impairment | Contraindicated in severe hepatic impairment; for Child-Pugh class A or B, reduce dose by 50% and monitor. |
| Pediatric use | For children 12 years and older: 250 mg to 500 mg orally three to four times daily; for children 6 to 11 years: 125 mg to 250 mg orally three to four times daily. |
| Geriatric use | Start at lower end of dosing range (250 mg to 500 mg orally three to four times daily) due to increased sensitivity and potential for sedation; monitor renal and hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for STRIFON FORTE DSC (STRIFON FORTE DSC).
| Breastfeeding | Diphenhydramine is excreted in breast milk in small amounts; M/P ratio not established. American Academy of Pediatrics considers compatible with breastfeeding, but may cause irritability or drowsiness in infant. Avoid high doses or long-term use. |
| Teratogenic Risk | STRIFON FORTE DSC (diphenhydramine) is FDA Pregnancy Category B. First trimester: No well-controlled studies; animal studies show no risk. Second/third trimesters: No known teratogenicity; avoid near term due to risk of neonatal withdrawal or respiratory depression. |
■ FDA Black Box Warning
Thioridazine has been associated with QTc interval prolongation and increased risk of life-threatening torsade de pointes, especially at higher doses. Coadministration with other drugs that inhibit CYP2D6 or prolong QTc interval is contraindicated.
| Serious Effects |
Hypersensitivity to any component; concurrent use of CYP3A4 inhibitors (e.g., macrolides, azole antifungals) with dihydroergotamine; severe hepatic or renal impairment; uncontrolled hypertension; ischemic heart disease; previous history of ergotamine-induced vasospasm; concurrent use of other ergot alkaloids or triptans within 24 hours; known QTc prolongation or concurrent use of QT-prolonging agents; concurrent use of CYP2D6 inhibitors with thioridazine.
| Precautions | Concurrent use of thioridazine with drugs that inhibit CYP2D6 (e.g., fluoxetine, paroxetine) may increase thioridazine levels and risk of QT prolongation. Caution in patients with hepatic impairment, cardiovascular disease, or electrolyte disturbances. Monitor for signs of serotonin syndrome when combined with other serotonergic drugs. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, and CNS effects (sedation, dizziness). In late pregnancy, monitor fetal heart rate for signs of distress. Assess neonatal respiratory status if used near delivery. |
| Fertility Effects | No known significant effects on human fertility. Animal studies show no impaired fertility at therapeutic doses. |